Chelation therapy and bone metabolism markers in thalassemia major

Loredana Pratelli, Elisabetta Verri, Monica Fortini, Stefano Marconi, Carola Zolezzi, Pier Maria Fornasari, Maria Rita Gamberini, Vincenzo De Sanctis

Research output: Contribution to journalArticlepeer-review


The aim of our study was to investigate the effects of subcutaneous desferrioxamine (DFX) and oral deferiprone (L1) therapy on bone metabolism markers in patients with thalassemia major. We studied 17 patients with thalassemia receiving long-term treatment with desferrioxamine, 20 patients receiving long-term treatment with deferiprone, and 15 healthy age-matched controls. The following investigations were performed: a) intact parathyroid hormone (PTH), 25-hydroxyvitamin D [25(OH)D], 1,25-dihydroxy-vitamin D [1,25(OH) 2D] as endocrine parameters; b) alkaline phosphatase (ALP), bone alkaline phosphatase (BALP), osteocalcin (OC); c) bone resorption biochemical markers in serum and urine pyridinium crosslinks: hydroxylysyl-pyridinoline (HP) and lysyl-pyridinoline (LP); d) serum levels of cytokines and growth factors: transforming growth factor-β1 (TGFβ1), insulin-like growth factor-I (IGF-I), interleukin-1β (IL-1β), interleukin-6 (IL-6), tumor necrosis factor-α (TNFα); e) serum levels of IGF binding protein-3 (IGFBP-3). No significant differences among all studied variables were found in patients with thalassemia treated with desferrioxamine or deferiprone. In contrast, significant differences were found between patients with thalassemia and the control group: intact PTH was significantly lower in patients with thalassemia than in the controls (p

Original languageEnglish
Pages (from-to)1335-1342
Number of pages8
JournalJournal of Pediatric Endocrinology and Metabolism
Issue number11
Publication statusPublished - Nov 2006


  • Bone metabolism
  • Chelation therapy
  • Osteoporosis
  • Thalassemia

ASJC Scopus subject areas

  • Endocrinology
  • Pediatrics, Perinatology, and Child Health


Dive into the research topics of 'Chelation therapy and bone metabolism markers in thalassemia major'. Together they form a unique fingerprint.

Cite this